long-term use of anabolic steroids is associated with left ventricular dysfunction
--------------------------------------------------------------------------------
in short- aas may increase the risk of heart failure.
of course many of us have always suspected the contributions of aas and cardiac disease among other impairments. but, the literature has been unclear and it is difficult to have studies using aas when they are illegal. the following study showed significant differences between groups including the left ventricle was significantly weaker during contraction in subjects using aas compared to non-users.
left ventricle dysfunciton can lead to heart failure and other cardiovascular diseases.
Quote:
Original Article
Long Term Anabolic-Androgenic Steroid Use is Associated with Left Ventricular Dysfunction
Aaron L. Baggish1,3; Rory B. Weiner1; Gen Kanayama2; James I. Hudson2; Michael H. Picard1; Adolph M. Hutter, Jr.1 and Harrison G. Pope, Jr.2
1 Massachusetts General Hospital and Harvard Medical School, Boston, MA;
2 McLean Hospital, Belmont, MA, and Harvard Medical School, Boston, MA
* Corresponding author; email: [email protected]
Background—Although illicit anabolic-androgenic steroid (AAS) use is widespread, the cardiac effects of long-term AAS use remain inadequately characterized. We compared cardiac parameters in weightlifters reporting long-term AAS use to those in otherwise similar weightlifters without prior AAS exposure.
Methods and Results—We performed 2-dimensional, tissue-Doppler, and speckle-tracking echocardiography to assess left ventricular (LV) ejection fraction, LV systolic strain, and conventional indices of diastolic function in long-term AAS users (n=12) and otherwise similar AAS non-users (n=7). AAS users (median [Q1, Q3] cumulative lifetime AAS exposure 468 [169-520] weeks) closely resembled non-users in age, prior duration of weightlifting, and current intensity of weight training. LV structural parameters were similar between the two groups. However, AAS users had significantly lower LV ejection fraction (50.6% [48.4, 53.6] versus 59.1% [58.0, 61.7]; p = 0.003 by Wilcoxon rank sum test, two-tailed); longitudinal strain (16.9% [14.0, 19.0] versus 21.0% [20.2, 22.9]; p = 0.004), and radial strain (38.3 [28.5, 43.7] versus 50.1 [44.3, 61.8]; p = 0.02). Ten of the 12 AAS users showed LV ejection fractions below the accepted limit of normal (55%). AAS users also demonstrated decreased diastolic function compared to non-users, as evidenced by a markedly lower E' velocity (7.4 [6.8, 7.9] versus 9.9 [8.3, 10.5]; p = 0.005) and E/A ratio (0.93 [0.88, 1.39] versus 1.80 [1.48, 2.00]; p = 0.003).
Conclusions—Cardiac dysfunction in long-term AAS users appears more severe than previously reported, and may be sufficient to increase the risk of heart failure.
--------------------------------------------------------------------------------
in short- aas may increase the risk of heart failure.
of course many of us have always suspected the contributions of aas and cardiac disease among other impairments. but, the literature has been unclear and it is difficult to have studies using aas when they are illegal. the following study showed significant differences between groups including the left ventricle was significantly weaker during contraction in subjects using aas compared to non-users.
left ventricle dysfunciton can lead to heart failure and other cardiovascular diseases.
Quote:
Original Article
Long Term Anabolic-Androgenic Steroid Use is Associated with Left Ventricular Dysfunction
Aaron L. Baggish1,3; Rory B. Weiner1; Gen Kanayama2; James I. Hudson2; Michael H. Picard1; Adolph M. Hutter, Jr.1 and Harrison G. Pope, Jr.2
1 Massachusetts General Hospital and Harvard Medical School, Boston, MA;
2 McLean Hospital, Belmont, MA, and Harvard Medical School, Boston, MA
* Corresponding author; email: [email protected]
Background—Although illicit anabolic-androgenic steroid (AAS) use is widespread, the cardiac effects of long-term AAS use remain inadequately characterized. We compared cardiac parameters in weightlifters reporting long-term AAS use to those in otherwise similar weightlifters without prior AAS exposure.
Methods and Results—We performed 2-dimensional, tissue-Doppler, and speckle-tracking echocardiography to assess left ventricular (LV) ejection fraction, LV systolic strain, and conventional indices of diastolic function in long-term AAS users (n=12) and otherwise similar AAS non-users (n=7). AAS users (median [Q1, Q3] cumulative lifetime AAS exposure 468 [169-520] weeks) closely resembled non-users in age, prior duration of weightlifting, and current intensity of weight training. LV structural parameters were similar between the two groups. However, AAS users had significantly lower LV ejection fraction (50.6% [48.4, 53.6] versus 59.1% [58.0, 61.7]; p = 0.003 by Wilcoxon rank sum test, two-tailed); longitudinal strain (16.9% [14.0, 19.0] versus 21.0% [20.2, 22.9]; p = 0.004), and radial strain (38.3 [28.5, 43.7] versus 50.1 [44.3, 61.8]; p = 0.02). Ten of the 12 AAS users showed LV ejection fractions below the accepted limit of normal (55%). AAS users also demonstrated decreased diastolic function compared to non-users, as evidenced by a markedly lower E' velocity (7.4 [6.8, 7.9] versus 9.9 [8.3, 10.5]; p = 0.005) and E/A ratio (0.93 [0.88, 1.39] versus 1.80 [1.48, 2.00]; p = 0.003).
Conclusions—Cardiac dysfunction in long-term AAS users appears more severe than previously reported, and may be sufficient to increase the risk of heart failure.
